CR20160070A - Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos - Google Patents

Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos

Info

Publication number
CR20160070A
CR20160070A CR20160070A CR20160070A CR20160070A CR 20160070 A CR20160070 A CR 20160070A CR 20160070 A CR20160070 A CR 20160070A CR 20160070 A CR20160070 A CR 20160070A CR 20160070 A CR20160070 A CR 20160070A
Authority
CR
Costa Rica
Prior art keywords
compounds
methods
triazolopiridine
compositions
same
Prior art date
Application number
CR20160070A
Other languages
English (en)
Inventor
Wei Li
Matthew W Cartwright
Christine Edwards
Simon C Goodacre
Snahel Patel
Nicholas C Ray
Mohammed Sajad
Po-Wai Yuen
Mark E Zak
Yun-Xing Cheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20160070A publication Critical patent/CR20160070A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En el presente documento se describen compuestos de Fórmula 0, Fórmula I y Fórmula II y métodos de uso como inhibidores de Janus cinasa.
CR20160070A 2013-09-05 2016-02-11 Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos CR20160070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874038P 2013-09-05 2013-09-05
PCT/CN2014/085276 WO2015032286A1 (en) 2013-09-05 2014-08-27 Triazolopyridine compounds, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20160070A true CR20160070A (es) 2016-04-01

Family

ID=52627792

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20160070A CR20160070A (es) 2013-09-05 2016-02-11 Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos

Country Status (17)

Country Link
US (4) US20160185780A1 (es)
EP (1) EP3041841B1 (es)
JP (1) JP6472803B2 (es)
KR (1) KR20160050080A (es)
CN (1) CN105745209B (es)
AU (1) AU2014317600A1 (es)
CA (1) CA2922770A1 (es)
CL (1) CL2016000496A1 (es)
CR (1) CR20160070A (es)
EA (1) EA201690523A1 (es)
IL (1) IL244066A0 (es)
MA (1) MA38884A1 (es)
MX (1) MX2016002764A (es)
PE (1) PE20161323A1 (es)
PH (1) PH12016500347A1 (es)
SG (1) SG11201601707PA (es)
WO (1) WO2015032286A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139212A1 (en) * 2015-03-04 2016-09-09 F. Hoffmann-La Roche Ag Triazolopyridine compounds and methods of use thereof
WO2017103188A1 (en) * 2015-12-18 2017-06-22 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof
JP6832342B2 (ja) * 2016-03-31 2021-02-24 武田薬品工業株式会社 複素環化合物
JP7050761B2 (ja) 2016-09-06 2022-04-08 エフ．ホフマン－ラ ロシュ アーゲー ８－（アゼチジン－１－イル）－［１，２，４］トリアゾロ［１，５－ａ］ピリジニル化合物、組成物及びその使用方法
CN109400610A (zh) * 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
KR20250057919A (ko) 2020-04-29 2025-04-29 릴레이 테라퓨틱스, 인크. PI3Kα 억제제 및 이의 사용 방법
WO2022187804A1 (en) * 2021-03-02 2022-09-09 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
TW202334136A (zh) * 2021-11-03 2023-09-01 美商傳達治療有限公司 PI3Kα抑制劑及其製造與使用方法
US12499866B2 (en) 2021-12-17 2025-12-16 Shure Acquisition Holdings, Inc. Adaptive acoustic echo cancellation for a stereo audio signal
US11746108B1 (en) * 2022-06-13 2023-09-05 Apm Therapeutics 1, Inc. Triazolopyridine polymorph A
CN120530113A (zh) 2022-12-16 2025-08-22 卡鲁娜治疗学有限公司 经取代的四氢吡咯并-吡啶酮化合物及其在治疗医学病状中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US6693116B2 (en) 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2009259867A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
RU2560153C2 (ru) * 2008-06-20 2015-08-20 Дженентек, Инк. Триазолпиридиновые соединения, ингибирующие jak, и способы
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
MX2011012961A (es) * 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체

Also Published As

Publication number Publication date
MA38884A1 (fr) 2017-06-30
EP3041841A4 (en) 2017-04-19
CN105745209A (zh) 2016-07-06
EP3041841B1 (en) 2019-06-05
US20190233441A1 (en) 2019-08-01
US9873709B2 (en) 2018-01-23
AU2014317600A1 (en) 2016-03-03
IL244066A0 (en) 2016-04-21
WO2015032286A1 (en) 2015-03-12
EP3041841A1 (en) 2016-07-13
JP6472803B2 (ja) 2019-02-20
KR20160050080A (ko) 2016-05-10
US20160185780A1 (en) 2016-06-30
JP2016529299A (ja) 2016-09-23
MX2016002764A (es) 2016-05-26
US20180298033A1 (en) 2018-10-18
EA201690523A1 (ru) 2016-07-29
CN105745209B (zh) 2018-10-23
CL2016000496A1 (es) 2016-10-07
PE20161323A1 (es) 2016-11-25
CA2922770A1 (en) 2015-03-12
PH12016500347A1 (en) 2016-05-16
US20170226132A1 (en) 2017-08-10
SG11201601707PA (en) 2016-04-28

Similar Documents

Publication Publication Date Title
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CO2017011754A2 (es) Amidas heterocíclicas como inhibidores de quinasa
DOP2018000088A (es) Amidas heterocíclicas como inhibidores de cinasas
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
UY35643A (es) Nuevos compuestos útiles como nematicidas, sus composiciones y métodos de uso
CR20150462A (es) Inhibidores de erk y sus usos
MX378288B (es) Inhibidores de pirimidina del fgfr4.
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
CL2015002303A1 (es) Derivados de pirrolo[2,3-d]pirimidina
MX2016015062A (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina los cuales son inhibidores de janus cinasas (jak).
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
MX373441B (es) Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt.